Octagam (Human Normal Immunoglobulin)

Human Normal Immunoglobulin, the active ingredient in Octagam, is an immunoglobulin presented as an intravenous solution for intravenous use. It treats primary immunodeficiency diseases and certain autoimmune conditions in patients requiring immune support and is manufactured in the EU in compliance with European pharmacopoeia standards.

GNH USA supplies Octagam as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Octagam is an immunoglobulin used to replace deficient antibodies and modulate immune responses in several immune‑related conditions. - Primary immunodeficiency diseases: provides antibody replacement to reduce infection frequency. - Chronic inflammatory demyelinating polyneuropathy (CIDP): helps improve muscle strength and functional ability. - Immune thrombocytopenic purpura (ITP): raises platelet counts and reduces bleeding risk. - Kawasaki disease: decreases inflammation and coronary artery complications. - Guillain‑Barré syndrome: supports recovery by modulating the immune attack on nerves.

Adverse reactions may occur with Octagam administration.

Common Side Effects: - Headache: mild to moderate pain often occurring during or after infusion. - Fever and chills: transient temperature elevation and shaking. - Fatigue: feeling of tiredness post‑infusion. - Nausea: mild gastrointestinal discomfort. - Infusion‑related reactions: erythema, itching, or mild hypotension. - Muscle aches: soreness in limbs or back.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Thromboembolic events: blood clots that may affect veins or arteries. - Acute renal failure: sudden loss of kidney function, especially in high‑risk patients. - Aseptic meningitis: inflammation of the meninges without infection. - Hemolytic anemia: destruction of red blood cells. - Severe hypotension: marked drop in blood pressure during infusion.

Before using Octagam, consider the following precautions. - Screen for IgA deficiency: patients with anti‑IgA antibodies are at higher risk of anaphylaxis. - Monitor renal function: ensure adequate hydration to reduce risk of renal impairment. - Assess thrombotic risk: avoid in patients with known hyperviscosity or recent thromboembolic events. - Use cautiously in patients with cardiovascular disease: monitor blood pressure and fluid status. - Pregnancy and lactation: administer only if clearly needed after risk‑benefit evaluation. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Octagam may interact with other medicines; awareness of these interactions helps ensure safe use.

Major Interactions (Avoid): - Live vaccines: may result in reduced vaccine efficacy and increased infection risk. - Rituximab and other B‑cell depleting agents: can diminish the therapeutic effect of IVIG. - High‑dose aspirin: may increase bleeding tendency.

Moderate Interactions (Monitor Closely): - Corticosteroids: combined immunosuppression may raise infection risk. - Diuretics: monitor renal function and electrolytes closely. - Anticoagulants: watch for signs of thrombosis or bleeding during therapy.